MIPSS70+ v2.0 predicts long-term survival in myelofibrosis after allogeneic HCT with the Flu/Mel conditioning regimen by Haris Ali, Ibrahim Aldoss, Dongyun Yang, Sally Mokhtari, Samer Khaled, Ahmed Aribi, Michelle Afkhami, Monzr M. Al Malki, Thai Cao, Matthew Mei, Margaret O’Donnell, Amandeep Salhotra, Vinod Pullarkat, Lixin Yang, Anthony S. Stein, Guido Marcucci, Stephen J. Forman, Ryotaro Nakamura, Raju Pillai, and David Snyder BloodAdv Volume 3(1):83-95 January 8, 2019 © 2019 by The American Society of Hematology

Haris Ali et al. Blood Adv 2019;3:83-95 © 2019 by The American Society of Hematology

Molecular profile of MF. (A) Mutations visualized as an oncoplot. Molecular profile of MF. (A) Mutations visualized as an oncoplot. Each column represents a sample and each row represents a different gene. The top barplot has the frequency of mutations for each patient, and the right-hand barplot has the frequency of mutations in each gene. By default, samples are ordered by the most mutated genes. (B) Mutational frequency of driver mutations and triple-negative (Triple Neg) mutations (pie chart), variant classification (first barplot), and frequently mutated genes per variant classifications (second barplot). (C) ASXL1 alterations. Haris Ali et al. Blood Adv 2019;3:83-95 © 2019 by The American Society of Hematology

Kaplan-Meier curves defining survival outcomes at 60 months after allo-HCT. Kaplan-Meier curves defining survival outcomes at 60 months after allo-HCT. Overall survival based on donor type and cytogenetics (A-B); impact of CBL and U2AF mutations on NRM (C-D). CIR est, cumulative incidence of relapse estimate; KM est, Kaplan-Meier estimate. Haris Ali et al. Blood Adv 2019;3:83-95 © 2019 by The American Society of Hematology

Kaplan-Meier curves demonstrating survival outcomes at 60 months after allo-HCT. Kaplan-Meier curves demonstrating survival outcomes at 60 months after allo-HCT. OS (A) and DFS (B) in intermediate-risk and high-risk patients per MIPSS70 classification; OS (C) and DFS (D) in intermediate-risk, high-risk, and VHR patients per MIPSS70+ v2.0 classification. NE, not estimated. Haris Ali et al. Blood Adv 2019;3:83-95 © 2019 by The American Society of Hematology